Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer

NCT03294694 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

33

Enrollment

OTHER

Sponsor class

Stopped Safety Implications

Conditions

Metastatic Hormone-Receptor-Positive (HR+) Breast Cancer
HER2-Negative Breast Cancer
Metastatic Epithelial Ovarian Cancer

Interventions

DRUG: Ribociclib
DRUG: PDR001
DRUG: Fulvestrant

Sponsor

Dana-Farber Cancer Institute

Collaborators

[object Object]